| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,320,000 |
| Market
Cap: |
4.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.34 - $4.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
10,250 |
50,250 |
57,251 |
| Total Buy Value |
$0 |
$37,160 |
$130,875 |
$174,456 |
| Total People Bought |
0 |
3 |
6 |
6 |
| Total Buy Transactions |
0 |
6 |
16 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
47,617 |
| Total Sell Value |
$0 |
$0 |
$0 |
$88,083 |
| Total People Sold |
0 |
0 |
0 |
7 |
| Total Sell Transactions |
0 |
0 |
0 |
15 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cormorant Global Healthcare Master Fund, Lp |
10% Owner |
– – • |
2016-11-04 |
4 |
B |
$7.27 |
$612,901 |
I/I |
76,000 |
2,526,882 |
1.5 |
- |
|
| Chen Bihua |
Director |
– • • |
2016-11-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,430,605 |
|
- |
|
| Cormorant Global Healthcare Master Fund, Lp |
10% Owner |
– – • |
2016-11-03 |
4 |
B |
$7.24 |
$146,763 |
I/I |
20,277 |
2,450,882 |
1.5 |
- |
|
| Barrett M James |
Director |
– • • |
2016-09-14 |
4 |
B |
$13.00 |
$5,999,994 |
I/I |
461,538 |
3,554,610 |
2.25 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-09-14 |
4 |
B |
$13.00 |
$5,999,994 |
D/D |
461,538 |
3,554,610 |
2.45 |
- |
|
| Berger Franklin M |
Director |
– • – |
2016-09-14 |
4 |
B |
$13.00 |
$899,990 |
D/D |
69,230 |
166,162 |
2.39 |
- |
|
| Chhabra Meenu |
President and CEO |
• • – |
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,218 |
10,218 |
|
- |
|
| Elan Science One Ltd |
10% Owner |
– – • |
2016-02-17 |
4 |
B |
$8.00 |
$1,000,000 |
I/I |
125,000 |
2,908,067 |
1.5 |
- |
|
| Elan Science One Ltd |
10% Owner |
– – • |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
2,783,067 |
2,783,067 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2016-02-17 |
4 |
B |
$8.00 |
$3,000,000 |
I/I |
375,000 |
1,877,812 |
0.01 |
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108,931 |
1,502,812 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-02-17 |
4 |
B |
$8.00 |
$7,202,592 |
D/D |
900,324 |
3,093,072 |
2.45 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,192,748 |
2,192,748 |
|
- |
|
| Barrett M James |
Director |
– • • |
2016-02-17 |
4 |
B |
$8.00 |
$7,202,592 |
I/I |
900,324 |
3,093,072 |
2.25 |
- |
|
| Barrett M James |
Director |
– • • |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
2,192,748 |
2,192,748 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2016-02-17 |
4 |
B |
$8.00 |
$3,000,000 |
D/D |
375,000 |
1,873,791 |
2.45 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,498,791 |
1,498,791 |
|
- |
|
| Werner Harold R |
10% Owner |
– – • |
2016-02-17 |
4 |
B |
$8.00 |
$3,000,000 |
I/I |
375,000 |
2,149,295 |
1.5 |
- |
|
| Werner Harold R |
10% Owner |
– – • |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,774,295 |
1,774,295 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2016-02-17 |
4 |
B |
$8.00 |
$200,000 |
D/D |
25,000 |
96,932 |
2.39 |
- |
|
| Berger Franklin M |
Director |
– • – |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
71,932 |
71,932 |
|
- |
|
| Walsh Christopher T Phd |
Director |
– • – |
2016-02-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,012 |
|
- |
|
| Kelly Jeffrey W. |
Director |
– • – |
2016-02-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
98,411 |
|
- |
|
148 Records found
|
|
Page 6 of 6 |
|
|
